The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Glucocorticoid therapy in giant cell arteritis: Duration and adverse outcomes
Abstract
Objective: To evaluate the course of glucocorticoid (GC) therapy and associated adverse events in a population‐based cohort of patients with giant cell arteritis (GCA). Methods: We identified 125 Olmsted County residents with GCA diagnosed between 1950 and 1991 and obtained followup information on the 120 patients who were diagnosed antemortem and agreed to participate in this study. Clinical variables, GC doses, and GC adverse events on each patient were recorded. The relationship between GC therapy and the development of adverse events was studied by the Cox and Anderson‐Gill proportional hazards models. Results: All patients were treated with GCs and responded rapidly (median initial dosage 60 mg prednisone/day). The dosage was later reduced according to the treating physicians' judgment. The median duration required to reach 7.5 mg/day was 6.5 months and the median duration required to reach 5 mg/day was 7.5 months. Relapses or recurrences occurred in 57 patients. For the 87 patients followed to discontinuation of GC therapy and permanent remission of GCA (median of 22 months), the total median dose of prednisone was 6.47 gm. Adverse events associated with GCs were recorded in 103 (86%) patients and 2 or more events occurred in 70 patients (58%). Age and higher cumulative dose of GCs were associated with the development of adverse GC side effects. Conclusion: GCs are therapeutically effective in GCA and the prednisone dosage was reduced to physiologic levels in three‐fourths of the patients within 1 year. However, most patients developed serious adverse side effects related to GCs, indicating that less toxic therapeutic measures are needed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Modeling Survival Data: Extending the Cox Model
Therneau, T. M., & Grambsch, P. M. (2000) · Statistics for Biology and Health · doi:10.1007/978-1-4757-3294-8 · Cited by 8,674
The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis
Hunder, G. G., Bloch, D. A., Michel, B. A., Stevens, M. B., Arend, W. P., Calabrese, L. H., Edworthy, S. M., Fauci, A. S., Leavitt, R. Y., Lie, J. T., et al. (1990) · Arthritis & Rheumatism · doi:10.1002/art.1780330810 · Cited by 2,539
Self-citationCooper, C., Atkinson, E. J., MichaelO'Fallon, W., & Dr. Melton, J. L. (1992) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650070214 · Cited by 1,528
History of the Rochester Epidemiology Project
Melton, L. J. (1996) · Mayo Clinic Proceedings · doi:10.4065/71.3.266 · Cited by 1,443
Recommendations for the prevention and treatment of glucocorticoid‐induced osteoporosis
American College of Rheumatology task force on Osteoporosis guidelines (1996) · Arthritis & Rheumatism · doi:10.1002/art.1780391104 · Cited by 848
Salvarani, C., Gabriel, S. E., O'Fallon, W. M., & Hunder, G. G. (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-123-3-199508010-00006 · Cited by 344
Self-citationTreatment of giant cell arteritis: Interleukin-6 as a biologic marker of disease activity
Weyand, C. M., Fulbright, J. W., Hunder, G. G., Evans, J. M., & Goronzy, J. J. (2000) · Arthritis & Rheumatism · doi:10.1002/1529-0131(200005)43:5<1041::aid-anr12>3.0.co;2-7 · Cited by 299
Self-citationAdverse outcomes of antiinflammatory therapy among patients with polymyalgia rheumatica
Gabriel, S. E., Sunku, J., Salvarani, C., O'Fallon, W. M., & Hunder, G. G. (1997) · Arthritis & Rheumatism · doi:10.1002/art.1780401022 · Cited by 239
Self-citationEpidemiology of polymyalgia rheumatica in olmsted county, minnesota, 1970–1991
Salvarani, C., Gabriel, S. E., Michael O'Fallon, W., & Hunder, G. G. (1995) · Arthritis & Rheumatism · doi:10.1002/art.1780380311 · Cited by 208
Self-citationDelecoeuillerie, G., Joly, P., Cohen de Lara, A., & Paolaggi, J. B. (1988) · Annals of the Rheumatic Diseases · doi:10.1136/ard.47.9.733 · Cited by 181
Kyle, V., & Hazleman, B. L. (1989) · Annals of the Rheumatic Diseases · doi:10.1136/ard.48.8.658 · Cited by 151
Long‐term Corticosteroid Treatment in Giant Cell Arteritis
Andersson, R., Malmvall, B., & Bengtsson, B. (1986) · Acta Medica Scandinavica · doi:10.1111/j.0954-6820.1986.tb02796.x · Cited by 120
Franzen, P., Sutinen, S., & von Knorring, J. (1992) · PubMed · Cited by 108
Musculoskeletal manifestations in a population-based cohort of patients with giant cell arteritis
Salvarani, C., & Hunder, G. G. (1999) · Arthritis & Rheumatism · Cited by 93
Self-citationPearce, G., Ryan, P. F. J., Delmas, P. D., Tabensky, D. A., & Seeman, E. (1998) · Lara D. Veeken · doi:10.1093/rheumatology/37.3.292 · Cited by 71
PREVENTION OF BLINDNESS IN GIANT CELL ARTERITIS BY CORTICOSTEROID TREATMENT
Myles, A. B., PERERA, T., & Ridley, M. G. (1992) · Lara D. Veeken · doi:10.1093/rheumatology/31.2.103 · Cited by 66
The Incidence of Diabetes Mellitus in Rochester, Minnesota, 1945–1969
Palumbo, P. J., & Labarthe, D. R. (1978) · Advances in metabolic disorders · doi:10.1016/b978-0-12-027309-6.50007-0 · Cited by 11
Cited by
Trial of tocilizumab in giant-cell arteritis
Stone, J. H., Tuckwell, K., Dimonaco, S., Klearman, M., Aringer, M., Blockmans, D., Brouwer, E., Cid, M. C., Dasgupta, B., Rech, J., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1613849 · Cited by 1,386
2018 Update of the EULAR recommendations for the management of large vessel vasculitis
Hellmich, B., Agueda, A., Monti, S., Buttgereit, F., de Boysson, H., Brouwer, E., Cassie, R., Cid, M. C., Dasgupta, B., Dejaco, C., et al. (2020) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2019-215672 · Cited by 1,200
Polymyalgia rheumatica and giant-cell arteritis
Salvarani, C., Cantini, F., & Hunder, G. G. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61077-6 · Cited by 767
Self-citationPolymyalgia Rheumatica and Giant Cell Arteritis
Ettlinger, R. E., Hunder, G. G., & Ward, L. E. (1978) · Annual Review of Medicine · doi:10.1146/annurev.me.29.020178.000311 · Cited by 687
Self-citationBlockmans, D., Ceuninck, L. D., Vanderschueren, S., Knockaert, D., Mortelmans, L., & Bobbaers, H. (2006) · Arthritis Care & Research · doi:10.1002/art.21699 · Cited by 628
Metadata
- Authors
- Proven, A., Gabriel, S. E., Orces, C., O'Fallon, W. M., & Hunder, G. G.
- Venue
- Arthritis Care & Research
- Publisher
- Wiley
- Published
- 2003-10-07
- Volume
- 49
- Issue
- 5
- Pages
- 703-708
- ISSN
- 0893-7524 (ISSN-L)
- 1529-0123
- OpenAlex
- W1995278898
- Cited by
- 612
- References
- 17
- FWCI
- 6.26
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.